This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other deletions of part of a chromosome Other deletions of part of a chromosome — Q93.5

Contents

No.ItemNo.ItemNo.Item
AClassification codes and basic information BSynonyms CAdult-onset considerations
1History and overview 2Causes and genetics 3Epidemiology
4Pathogenesis and pathophysiology 5Clinical symptoms 6Clinical signs
7Screening 8Diagnosis 9Treatment
10Prognosis 11Complications and comorbidities 12Genetic counseling and prevention
13References

A. Classification codes and basic information

ICD-10 codeQ93.5
Special Copayment Reduction codeV217
Re-approval cycle5 years
Main name (Korean)Other deletions of part of a chromosome
Main name (English)Other deletions of part of a chromosome
Included disorders22q11.2 deletion (DiGeorge/CATCH22), Angelman syndrome (15q11-q13 maternal), Smith-Magenis syndrome (17p11.2), Williams syndrome (7q11.23)

B. Synonyms

Korean synonymsCATCH22 syndrome; Angelman syndrome; Magenis syndrome; Williams syndrome
English synonymsCATCH22 syndrome; DiGeorge syndrome (chromosomal form); Angelman syndrome; Smith-Magenis syndrome; Williams syndrome; Williams-Beuren syndrome; Velocardiofacial syndrome

C. Adult-onset considerations

Each syndrome in the Q93.5 category requires ongoing medical management in adulthood as well. In 22q11.2 deletion syndrome, the risk of schizophrenia spectrum disorders (10~25%) and autoimmune diseases increases in adulthood. In adults with Angelman syndrome, seizure control, maintenance of mobility and prevention of obesity are key issues. In adults with Smith-Magenis syndrome, sleep disturbance and behavioral problems persist. In adults with Williams syndrome, monitoring of cardiovascular complications (progression of aortic stenosis), diabetes, hypertension and renal dysfunction is important.


1. History and overview

ICD-10 code Q93.5, "Other deletions of part of a chromosome", covers various chromosomal microdeletion syndromes not assigned a specific code. This category includes several clinically important major microdeletion syndromes, each with a different history of discovery and mechanism.

22q11.2 deletion syndrome (CATCH22/DiGeorge), as described earlier, began with DiGeorge's clinical description in 1965, and the 22q11.2 microdeletion was identified in the 1990s. The acronym CATCH22 was proposed by Wilson et al. in 1993 (Cardiac defects, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia, 22q11).

Angelman syndrome originated in 1965 when the British pediatrician Harry Angelman described severe intellectual disability, seizures, a happy demeanor and an unusual gait in 3 children and called them "puppet children". The 15q11-q13 deletion was discovered in 1987, and in the 1990s, as the roles of maternal imprinting and the UBE3A gene were elucidated, it became a paradigm case of imprinting genetics.

Smith-Magenis syndrome was first described by Uhrich and Rice in 1982 and established as a clinical syndrome by Smith, Dykens, Greenberg et al. in 1986. The 17p11.2 deletion was first identified by cytogenetic analysis in 1986, and RAI1 was later found to be the main responsible gene.

Williams syndrome derives from the 1961 description by the New Zealand cardiologist John C.P. Williams of patients with supravalvular aortic stenosis, mental retardation and a distinctive facial appearance. In 1963, the German A. J. Beuren reported additional cases, so it is also called Williams-Beuren syndrome. The 7q11.23 deletion was identified by Ewart et al. in 1993, and haploinsufficiency of the elastin (ELN) gene was established as the main cause of the cardiovascular phenotype.


2. Causes and genetics

Each syndrome in the Q93.5 category is caused by a microdeletion of a specific chromosomal region, and non-allelic homologous recombination (NAHR) is the most common mechanism.

22q11.2 deletion syndrome

A deletion of about 3 Mb (or a 1.5 Mb smaller deletion) at band 11.2 of the long arm of chromosome 22, caused by NAHR between low-copy repeats (LCR22A-D). TBX1 is the main responsible gene, and CRKL, DGCR8 and others also contribute to the phenotype. 90% are de novo and 10% are autosomal dominantly inherited.

Angelman syndrome

A maternal deletion at bands 11-13 of the long arm of chromosome 15 (15q11.2-q13) is the most common cause (about 70%). The rest are due to paternal uniparental disomy (UPD), UBE3A mutations and imprinting center (ICR) defects. Because the UBE3A (E6-AP ubiquitin ligase) gene is an imprinted gene of which only the maternal allele is expressed in the brain, a maternal 15q11-q13 deletion affects neural function.

Smith-Magenis syndrome

Most cases (90%) are an approximately 3.7 Mb deletion at band 11.2 of the short arm of chromosome 17 (17p11.2), and in a minority, point mutations of the RAI1 gene are the cause. RAI1 is a transcriptional regulator involved in neurodevelopment, circadian rhythm and lipid metabolism. Most cases occur de novo.

Williams syndrome

An approximately 1.55 Mb deletion at band 11.23 of the long arm of chromosome 7 (7q11.23), caused by NAHR between LCR7A-C. About 25 genes are deleted, including ELN (elastin), LIMK1 and GTF2I, GTF2IRD1. ELN haploinsufficiency explains supravalvular aortic stenosis, and GTF2I/GTF2IRD1 deletion explains the distinctive cognitive profile and hypersociability. Over 99% occur de novo.


3. Epidemiology

The prevalence of each syndrome is summarized separately. Combined, the prevalence of the Q93.5 code as a whole is considerably high.

SyndromeDeletion locationBirth frequencyMode of inheritance
22q11.2 deletion syndrome22q11.21/4,000Autosomal dominant; 90% de novo
Angelman syndrome15q11-q13 (maternal)1/12,000~20,000Imprinting-related; mostly de novo
Smith-Magenis syndrome17p11.21/15,000~25,000Autosomal dominant; mostly de novo
Williams syndrome7q11.231/7,500~10,000Autosomal dominant; >99% de novo

22q11.2 deletion syndrome is known as the most common chromosomal deletion syndrome after Down syndrome. In none of the syndromes are there particular risk factors (such as maternal age); they mainly arise by chance during meiosis. In Korea as well, each syndrome is registered for Special Copayment Reduction, and regular follow-up management is provided.


4. Pathogenesis and pathophysiology

The pathophysiology of each syndrome differs according to the responsible genes in the deleted region, but haploinsufficiency is the common mechanism.

22q11.2 deletion: TBX1 and neural crest cell development

TBX1 (T-box transcription factor 1) is essential for development of the pharyngeal arches and pharyngeal pouches. TBX1 haploinsufficiency results in abnormal development of the thymus, parathyroid glands, aortic arch and palate. DGCR8 deletion causes abnormal miRNA processing, contributing to neurodevelopmental and psychiatric phenotypes. CRKL deletion affects neural crest cell migration.

Angelman syndrome: UBE3A imprinting and neural function

Because only the maternal allele of UBE3A is expressed in the brain (imprinting), a maternal 15q11-q13 deletion results in complete loss of UBE3A protein expression. UBE3A is involved in long-term potentiation (LTP) and learning and memory through ubiquitination of synaptic proteins. LTP abnormalities, learning impairment and seizures have been reproduced in UBE3A-deficient mouse models. GABA receptor genes (GABRB3, GABRA5, etc.) are also included in the deleted region and contribute to seizure susceptibility.

Smith-Magenis syndrome: RAI1 and circadian rhythm

RAI1 regulates the function of nuclear receptors and transcription factors and is particularly involved in regulating expression of the CLOCK gene. RAI1 haploinsufficiency inverts the normal pattern of melatonin secretion (increased secretion during the day, decreased at night), causing severe sleep disturbance. RAI1 is also involved in adipocyte differentiation and appetite regulation, explaining the tendency toward obesity.

Williams syndrome: ELN and vascular abnormalities

ELN (elastin) haploinsufficiency promotes vascular smooth muscle proliferation, causing vascular abnormalities such as supravalvular aortic stenosis (SVAS) and pulmonary artery stenosis. GTF2I deletion is associated with hypersociability, anxiety and visuospatial cognitive deficits, and LIMK1 deletion with impaired visuospatial construction ability.


5. Clinical symptoms

Each syndrome in the Q93.5 category has a distinct characteristic clinical phenotype. The key clinical symptoms of each syndrome are summarized.

22q11.2 deletion syndrome

It shows a highly variable phenotype (more than 180 abnormalities reported), and the main symptoms include congenital heart defects (conotruncal anomalies: tetralogy of Fallot, interrupted aortic arch, ventricular septal defect, etc.), immunodeficiency (T cell reduction, thymic hypoplasia/aplasia), hypocalcemia (parathyroid hypoplasia), palatal abnormalities (submucous cleft palate, velopharyngeal insufficiency), facial dysmorphism (long face, bulbous nose, tubular ears), psychiatric abnormalities (schizophrenia, bipolar disorder, ADHD), and developmental delay and learning disability.

Angelman syndrome

Characterized by severe intellectual disability and absent speech or extreme speech deficit. A happy demeanor and frequent laughter (inappropriately cheerful mood) are prominent, which is the origin of the old name "happy puppet syndrome". There is a characteristic gait abnormality with raised arms and wide-based legs, seizures in over 90% (especially myoclonic seizures, atypical absence seizures), and EEG abnormalities. Microcephaly, blond hair, fair skin and blue eyes are observed in some.

Smith-Magenis syndrome

Severe sleep disturbance (daytime sleepiness, nighttime awakening, early waking) is the most characteristic feature. Behavioral features prominently include self-hugging, hand-wringing, hyperactivity and self-injury (head banging, pulling out fingernails and toenails). Intellectual disability, delayed speech development, a short, stocky build, a flat face and a prominent forehead are characteristic. Eye abnormalities (iris Herbert nodules, corneal abnormalities) are observed in 75%.

Williams syndrome

Characterized by a very sociable and friendly personality ("cocktail party personality"), with excessive approach even to strangers. There is intellectual disability, but language ability is relatively preserved (fluent language use for the level of intellectual disability). Visuospatial cognition and visual-motor integration are severely impaired. Musical talent is unusually preserved. Cardiovascular symptoms (chest pain and exercise intolerance related to SVAS), a distinctive facial appearance (elfin face: broad forehead, stellate iris, upturned nasal tip, thick lips), hypercalcemia and renal malformations are characteristic.


6. Clinical signs

The characteristic physical examination findings of each syndrome are described.

Physical signs of 22q11.2 deletion syndrome

Facial dysmorphism (long face, tubular nose, microtia, widely spaced eyes), hypernasal speech due to velopharyngeal insufficiency, thymic hypoplasia (loss of thymic shadow on chest X-ray), parathyroid hypoplasia (carpopedal spasm, tetany due to hypocalcemia) and recurrent infections are prominent. Hearing loss accompanies it in 30%.

Physical signs of Angelman syndrome

Characterized by microcephaly (normal at birth, with microcephaly developing later), exotropia, hypopigmentation (blond hair, fair skin), protruding tongue, widely spaced teeth, and high-amplitude slow waves and spike-slow wave complex patterns on EEG. The seizure-related EEG findings are relatively specific for Angelman syndrome.

Physical signs of Smith-Magenis syndrome

A flat, square-shaped face, thick lips, malocclusion, short arms and legs, and scoliosis are seen. Herbert nodules (Brushfield-like spots) are observed in the iris. A short neck, hoarse voice and broad hands are also characteristic.

Physical signs of Williams syndrome

Elfin face (stellate iris pattern, periorbital fullness, broad forehead), heart murmur (SVAS — aortic stenosis murmur), renal malformations (horseshoe kidney, renal artery stenosis). Musculoskeletal abnormalities (joint contractures, scoliosis), hernias and obesity are also commonly present.


7. Screening

Large-scale neonatal screening for syndromes in the Q93.5 category is currently not performed. However, NIPT during pregnancy can detect some microdeletions such as 22q11.2 deletion and Williams syndrome, in which case invasive testing is needed for confirmation. When a congenital heart defect is found, screening for 22q11.2 and Williams syndrome is considered. If hypocalcemia is present in the neonatal period, 22q11.2 deletion must be ruled out. When seizures, intellectual disability, delayed speech development or behavioral abnormalities are present, a stepwise diagnostic approach based on the clinical features specific to each syndrome is recommended.


8. Diagnosis

Confirmation of each syndrome in the Q93.5 category is by cytogenetic or molecular genetic testing.

Chromosomal microarray (CMA)

Recommended as the first-tier diagnostic test. Array CGH or SNP array precisely determines the location and size of the deletion. All deletions, including 22q11.2, 7q11.23, 17p11.2 and 15q11-q13, can be detected simultaneously with a single test. In the diagnosis of Angelman syndrome, CMA alone cannot distinguish UPD, ICR defects or UBE3A mutations, so additional testing is needed.

FISH

When a specific syndrome is strongly suspected clinically, FISH for the corresponding locus is rapid and cost-effective. 22q11.2 FISH, elastin (ELN) FISH, RAI1 FISH, etc. are used.

Angelman syndrome-specific testing

Maternal imprinting abnormalities of 15q11-q13 are confirmed by methylation analysis (methylation-specific PCR or MLPA). If CMA is negative, UBE3A gene sequencing is performed to test for point mutations. Methylation analysis differentiates maternal deletion, paternal UPD and ICR defects.

NGS panels and WES/WGS

When clinical symptoms are atypical or differentiation among several syndromes is difficult, whole exome or whole genome sequencing is performed. WES/WGS can simultaneously evaluate causes other than deletions (such as single-gene mutations).


9. Treatment

There is as yet no definitive gene therapy for any of the syndromes, and the focus is on symptom management and prevention of complications.

22q11.2 deletion syndrome

Congenital heart defects are corrected by early surgery. With T cell deficiency, live vaccines are avoided, and in severe immunodeficiency, thymus transplantation may be indicated. Hypocalcemia is managed with calcium and vitamin D supplementation. Psychiatric abnormalities in adulthood (schizophrenia, etc.) are treated with antipsychotics, but caution is needed because patients with 22q11.2 deletion may have increased sensitivity to some drugs. Dose adjustment considering the neural vulnerability due to DGCR8 deletion is needed.

Angelman syndrome

Seizures are controlled with valproic acid, clonazepam, levetiracetam, etc., but carbamazepine and phenytoin are avoided because they can worsen EEG abnormalities. Speech therapy and introduction of AAC are important. At the research stage, ASO (antisense oligonucleotide)-based therapy activating paternal UBE3A expression is in clinical trials.

Smith-Magenis syndrome

Management of sleep disturbance is key. Combination therapy suppressing daytime melatonin secretion with beta-1 adrenergic receptor blockers (acebutolol, atenolol) and evening melatonin supplementation is reported to be effective. Behavioral therapy (ABA) and a structured educational environment are important.

Williams syndrome

If vascular stenosis such as SVAS is present, it is corrected by angioplasty or surgery. If hypercalcemia is present, calcium and vitamin D restriction and, if needed, use of bisphosphonates are considered. Renal function and blood pressure are monitored regularly. Social skills education and vocational training are important for quality of life in adulthood.


10. Prognosis

The prognosis of syndromes in the Q93.5 category varies with each syndrome and the individual patient's complications. In 22q11.2 deletion syndrome, life expectancy is close to normal when there is no heart defect or it has been corrected, but schizophrenia in adulthood (10~25%) is the main cause of functional decline. In Angelman syndrome, survival is close to normal, but severe intellectual disability and seizures persist throughout life and independent living is difficult. In Smith-Magenis syndrome, intellectual disability and behavioral problems persist, but survival is normal. In Williams syndrome, there is a risk of sudden death when SVAS is severe, and obesity, hypertension, diabetes and declining renal function in adulthood can be major causes of death. Early diagnosis and intensive multidisciplinary management improve prognosis.


11. Complications and comorbidities

The major complications commonly seen in syndromes of the Q93.5 category are summarized. For syndrome-specific complications, refer to the clinical symptoms and treatment sections above.


12. Genetic counseling and prevention

Because most syndromes in the Q93.5 category occur de novo, the recurrence risk for parents of an affected child is generally less than 1%. However, if one parent has a 22q11.2 deletion (autosomal dominant), the recurrence risk is 50%. In Angelman syndrome, the recurrence risk differs by the causative mechanism (deletion, UPD, ICR defect, UBE3A mutation), so identification of the causative mechanism is essential for genetic counseling. Because Williams syndrome is an autosomal dominant disorder, it is transmitted from an affected parent to a child with 50% probability. In all cases, prenatal diagnosis (CMA or FISH) is recommended in the next pregnancy.


13. References

  1. McDonald-McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071. PMID: 27189754. DOI: 10.1038/nrdp.2015.71
  2. Angelman H. 'Puppet' children: a report on three cases. Dev Med Child Neurol. 1965;7(6):681–688. (original article)
  3. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15(1):70–73. PMID: 8988171
  4. Smith ACM, Dykens E, Greenberg F. Behavioral phenotype of Smith-Magenis syndrome. Am J Med Genet. 1998;81(2):179–185. PMID: 9613862
  5. De Leersnyder H, De Blois MC, Vekemans M, et al. Beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. J Med Genet. 2001;38(9):586–590. PMID: 11546825
  6. Williams JC, Barratt-Boyes BG, Lowe JB. Supravalvular aortic stenosis. Circulation. 1961;24:1311–1318. PMID: 14488182
  7. Ewart AK, Morris CA, Atkinson D, et al. Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet. 1993;5(1):11–16. PMID: 8220421
  8. Morris CA. Williams syndrome. In: Adam MP, et al., eds. GeneReviews. Seattle: University of Washington; 1999 (updated 2017). PMID: 20301427
  9. Morrow BE, McDonald-McGinn DM, Emanuel BS, Vermeesch JR, Scambler PJ. Molecular genetics of 22q11.2 deletion syndrome. Am J Med Genet A. 2018;176(10):2070–2081. PMID: 30380194. DOI: 10.1002/ajmg.a.40504
  10. Thibert RL, Larson AM, Hsieh DT, Raby AR, Thiele EA. Neurologic manifestations of Angelman syndrome. Pediatr Neurol. 2013;48(4):271–279. PMID: 23498566. DOI: 10.1016/j.pediatrneurol.2012.09.015